# DoD VRP, Translational Research Award

Source: https://welltoldgrants.com/grants/ht942524vrptra-dod-vrp-translational-research-award/  
Official notice: https://www.grants.gov/search-results-detail/354238

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $1.6 million in total. Applications closed on November 12, 2024.

| Field | Value |
|---|---|
| Opportunity number | HT942524VRPTRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | November 12, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $1.6 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The FY24 VRP TRA is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military exposure. Successful applications to the FY24 VRP TRA should establish a clear path to transforming a promising discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. For new drug or device development, the investigative team should include at least one collaborator with expertise in the regulatory approval process. It is expected that, if applicable, an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application or international equivalent will be submitted to a Regulatory Agency during or by the end of the period of performance. For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency. Partnering PI Option: The FY24 VRP TRA includes an option for two Principal Investigators (PIs). One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission. Research involving animals, human subjects, and human anatomical substances is permitted. The FY24 VRP TRA allows funding for a pilot clinical trial (PCT) component, but not a full-scale clinical trial. In contrast to full-scale clinical trials that are designed to determine safety or efficacy, the purpose of the PCT is to inform the feasibility, rationale, and design of subsequent clinical trials through limited clinical testing of a novel intervention.

## Questions people ask

### Is HT942524VRPTRA still open?

No. It closed on November 12, 2024. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD VRP, Translational Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD VRP, Translational Research Award?

Closed November 12, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $1.6 million in total for one award.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.